Clinical trial · Interventional
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors
NCT00046111CI-TRIAL-00027823completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare two capsules of topotecan made by slightly different methods. This will be done by giving the drug made by the two different methods to patients orally and testing blood levels.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer, Small Cell | Lung Small Cell Carcinoma | ALIAS | 0.90 |
| Solid Tumor Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Primary Group
- description
- 40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
- interventionNames
- Drug: topotecan
Primary outcomes (1)
- measure
- To determine the bioequivalence of new formulation (test) of oral topotecan relative to the current Phase III formulation (reference) of oral topotecan by comparing AUC in patients with advanced solid tumors.
- timeFrame
- Four weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent * Patients with confirmed advanced solid tumors. * No prior chemotherapy within 5 years of the diagnosis of SCLC (small cell lung cancer). * At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. * Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. Exclusion criteria: * Women who are pregnant or lactating. * Patients of child bearing potential refusing to practice adequate contraception. * Patients with uncontrolled vomiting. * Active infection. * Patients with clinical evidence of any gastrointestinal (GI) conditions which would alter GI absorption or GI motility. * Patients requiring treatment with cyclosporin A. * Severe medical problems other than the cancer, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. * Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for cancer treatment. * Use of investigational drug within 30 days prior to the first dose of study medication.
References
Publications (0)
Data not yet available
No reference posted for this study.